NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free ENTA Stock Alerts $13.91 +0.35 (+2.58%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$13.38▼$13.9450-Day Range$12.37▼$17.4652-Week Range$8.08▼$37.14Volume116,755 shsAverage Volume247,670 shsMarket Capitalization$294.34 millionP/E RatioN/ADividend YieldN/APrice Target$19.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Enanta Pharmaceuticals alerts: Email Address Enanta Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside39.0% Upside$19.33 Price TargetShort InterestBearish13.94% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.31Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.90) to ($4.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.41 out of 5 starsMedical Sector285th out of 908 stocksPharmaceutical Preparations Industry128th out of 419 stocks 3.1 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.94% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 1.8 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.64% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($4.90) to ($4.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Stock News HeadlinesApril 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).April 29, 2024 | businesswire.comEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024April 17, 2024 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024March 19, 2024 | money.usnews.comEnanta Pharmaceuticals IncMarch 13, 2024 | seekingalpha.comENTA Enanta Pharmaceuticals, Inc.March 11, 2024 | finance.yahoo.comENTA Oct 2024 20.000 callMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).March 11, 2024 | finance.yahoo.comENTA Oct 2024 22.500 callMarch 11, 2024 | finance.yahoo.comENTA Oct 2024 10.000 putMarch 6, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma ConferenceFebruary 12, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportFebruary 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)February 9, 2024 | markets.businessinsider.comMaintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline PotentialFebruary 8, 2024 | finance.yahoo.comQ1 2024 Enanta Pharmaceuticals Inc Earnings CallFebruary 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call TranscriptFebruary 7, 2024 | benzinga.comRecap: Enanta Pharma Q1 EarningsFebruary 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q1 2024 Results: Royalty Revenue Declines Amid ...February 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue EstimatesFebruary 7, 2024 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ETFebruary 6, 2024 | benzinga.comEarnings Preview For Enanta PharmaFebruary 6, 2024 | finance.yahoo.comEnanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023January 5, 2024 | markets.businessinsider.comBuy Rating on Enanta Pharmaceuticals Amidst Promising RSV Program Developments and Strategic Expansion into CSU MarketJanuary 5, 2024 | finance.yahoo.comStrength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?January 4, 2024 | finance.yahoo.comEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare ConferenceSee More Headlines Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today5/02/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees145Year FoundedN/APrice Target and Rating Average Stock Price Target$19.33 High Stock Price Target$28.00 Low Stock Price Target$11.00 Potential Upside/Downside+42.6%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,820,000.00 Net Margins-187.77% Pretax Margin-184.73% Return on Equity-60.38% Return on Assets-32.29% Debt Debt-to-Equity RatioN/A Current Ratio6.25 Quick Ratio6.25 Sales & Book Value Annual Sales$79.20 million Price / Sales3.62 Cash FlowN/A Price / Cash FlowN/A Book Value$10.29 per share Price / Book1.32Miscellaneous Outstanding Shares21,160,000Free Float18,270,000Market Cap$286.93 million OptionableOptionable Beta0.54 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Jay R. Luly Ph.D. (Age 68)President, CEO & Director Comp: $1.25MMr. Paul J. Mellett Jr. (Age 69)Senior VP of Finance & Administration and CFO Comp: $666.84kDr. Yat Sun Or Ph.D. (Age 72)Senior VP of Research & Development and Chief Scientific Officer Comp: $729.31kMr. Nathaniel S. Gardiner J.D. (Age 70)Senior VP, General Counsel & Secretary Comp: $672.67kMr. Brendan Luu (Age 49)Senior Vice President of Business Development Comp: $622.86kMs. Jennifer VieraSenior Director of Investor Relations & Corporate CommunicationsMs. Tara Lynn Kieffer Ph.D. (Age 46)Senior Vice President of New Product Strategy & Development Comp: $496.85kDr. Scott T. Rottinghaus M.D. (Age 50)Senior VP & Chief Medical Officer Comp: $616.73kMore ExecutivesKey CompetitorsCorMedixNASDAQ:CRMDXOMANASDAQ:XOMAVerrica PharmaceuticalsNASDAQ:VRCAContineum TherapeuticsNASDAQ:CTNMESSA PharmaNASDAQ:EPIXView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsSold 24,776 shares on 5/1/2024Ownership: 0.117%Hennion & Walsh Asset Management Inc.Sold 2,062 shares on 4/17/2024Ownership: 0.065%Pennant Investors LPBought 35,100 shares on 2/14/2024Ownership: 0.166%Armistice Capital LLCSold 36,000 shares on 2/13/2024Ownership: 9.754%Trexquant Investment LPSold 13,949 shares on 2/9/2024Ownership: 0.561%View All Insider TransactionsView All Institutional Transactions ENTA Stock Analysis - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price target for 2024? 6 equities research analysts have issued twelve-month target prices for Enanta Pharmaceuticals' shares. Their ENTA share price targets range from $11.00 to $28.00. On average, they anticipate the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 39.0% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2024? Enanta Pharmaceuticals' stock was trading at $9.41 at the beginning of the year. Since then, ENTA stock has increased by 47.8% and is now trading at $13.91. View the best growth stocks for 2024 here. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our ENTA earnings forecast. How can I listen to Enanta Pharmaceuticals' earnings call? Enanta Pharmaceuticals will be holding an earnings conference call on Monday, May 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its earnings results on Wednesday, February, 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.18) by $0.40. The biotechnology company had revenue of $18 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative trailing twelve-month return on equity of 60.38%. What ETF holds Enanta Pharmaceuticals' stock? Amplify Treatments, Testing and Advancements ETF holds 4,991 shares of ENTA stock, representing 0.73% of its portfolio. What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BNP Paribas Financial Markets (0.12%) and Hennion & Walsh Asset Management Inc. (0.06%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus, Terry Vance and Yat Sun Or. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENTA) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.